Protection of neurons from high glucose‐induced injury by deletion of MAD2B

Diabetic encephalopathy may lead to cognitive deficits in diabetic patients and diminish quality of life. It has been shown that protracted hyperglycaemia is directly associated with neuronal apoptosis, which is involved in diabetic encephalopathy. The anaphase‐promoting complex (APC) is essential for the survival of post‐mitotic neurons. In our previous study, we found that the mitotic arrest deficient protein MAD2B, one of APC inhibitors, was expressed in neurons in central nervous system. However, whether MAD2B is involved in hyperglycaemia‐induced apoptosis and thus takes part in diabetic encephalopathy is still unknown. To address this issue, we first explored the expression of MAD2B and cyclin B1 detected by immunofluorescence and Western blot. It was found that hyperglycaemia remarkably increased the expression of MAD2B and accumulation of cyclin B1 in cortices of diabetes mellitus rat model and in cultured primary neurons. To further explore the role of MAD2B in hyperglycaemia‐induced neuronal injury, we depleted MAD2B expression by a specifically targeted shRNA against MAD2B. We observed that MAD2B deficiency alleviated cyclin B1 expression and apoptotic neuronal death. These results demonstrate that MAD2B expression is the main culprit for accumulation of cyclin B1 and apoptosis in neurons under high glucose. Moreover, inhibition of the expression of MAD2B prevented neurons from entering an aberrant S phase that led differentiated neurons into apoptotic cell death. These results suggest that hyperglycaemia induced neuronal apoptosis through inducing expression of MAD2B, which represents a novel mechanism of diabetic encephalopathy.     

Tumour necrosis factor‐α promotes liver ischaemia‐reperfusion injury through the PGC‐1α/Mfn2 pathway

Tumour necrosis factor (TNF)‐α has been considered to induce ischaemia‐reperfusion injury (IRI) of liver which is characterized by energy dysmetabolism. Peroxisome proliferator–activated receptor‐γ co‐activator (PGC)‐1α and mitofusion2 (Mfn2) are reported to be involved in the regulation of mitochondrial function. However, whether PGC‐1α and Mfn2 form a pathway that mediates liver IRI, and if so, what the underlying involvement is in that pathway remain unclear. In this study, L02 cells administered recombinant human TNF‐α had increased TNF‐α levels and resulted in down‐regulation of PGC‐1α and Mfn2 in a rat liver IRI model. This was associated with hepatic mitochondrial swelling, decreased adenosine triphosphate (ATP) production, and increased levels of reactive oxygen species (ROS) and alanine aminotransferase (ALT) activity as well as cell apoptosis. Inhibition of TNF‐α by neutralizing antibody reversed PGC‐1α and Mfn2 expression, and decreased hepatic injury and cell apoptosis both in cell culture and in animals. Treatment by rosiglitazone sustained PGC‐1α and Mfn2 expression both in IR livers, and L02 cells treated with TNF‐α as indicated by increased hepatic mitochondrial integrity and ATP production, reduced ROS and ALT activity as well as decreased cell apoptosis. Overexpression of Mfn2 by lentiviral‐Mfn2 transfection decreased hepatic injury in IR livers and L02 cells treated with TNF‐α. However, there was no up‐regulation of PGC‐1α. These findings suggest that PGC‐1α and Mfn2 constitute a regulatory pathway, and play a critical role in TNF‐α‐induced hepatic IRI. Inhibition of the TNF‐α or PGC‐1α/Mfn2 pathways may represent novel therapeutic interventions for hepatic IRI.     

高浓度藏红花溶液导致大鼠肝损伤中caspase-3、bcl-2、NF-kB表达及意义

目的：通过研究高浓度藏红花溶液引起肝损伤大鼠肝功能、肝组织病理及肝组织中半胱氨酸蛋白酶-3（caspase-3）,bcl-2,NF-kB表达,探讨半胱氨酸蛋白酶-3（caspase-3）,bcl-2,NF-kB在高浓度藏红花溶液导致的肝损伤中的作用及机制。方法：清洁级雄性大鼠45只,随机分为3组,每组15只,分别标记为A组（藏红花组）;B组（酒精组,阳性对照）;C组（生理盐水组,阴性对照）。分别给予藏红花高浓度水煎浓缩溶液、60%酒精、生理盐水灌胃共6周。第6周末,心腔取血测定ALT、AST。肝组织HE染色,免疫组化方法检测细胞凋亡相关蛋白Caspase-3及调控基因Bcl-2、NF-kB的表达。结果：藏红花组大鼠肝功能ALT、AST升高,肝组织正常结构消失,肝细胞肿胀坏死,部分碎裂,凋亡蛋白caspase-3,bcl-2,NF-kB表达增加（69.6%±16.7%vs 5.3%±1.6%;55.4%±14.5%vs4.5%±2.8%;44.1%±12.6%vs2.5%±1.9%;P〈0.05）。结论：高浓度藏红花溶液可以引起大鼠肝损伤,肝组织caspase-3,bcl-2,NF-kB表达增加,细胞凋亡机制参与了藏红花肝损伤过程。     

依达拉奉对犬自体肾移植缺血再灌注损伤的保护作用研究

目的：探讨依达拉奉对犬自体肾移植缺血再灌注损伤的影响及机制。方法：将18 只体重匹配的健康杂种犬随机分为假手术组（S组）、依达拉奉组（ED组）、生理盐水组（PS 组）,每组各6只。S 组仅进行肾手术切除;ED组在阻断前在供体静脉内注入依达拉奉10 mg/kg,然后使用200 mL加入依达拉奉10 mg/kg 的UW液灌洗供体肾并在同样的保存液中保存供体肾8 小时,且再灌注开始时立即在受体静脉内给予依达拉奉10 mg/kg;PS 组同法使用相同体积的生理盐水。再灌注4 h 后检测MDA、MPO、SOD、iNOS、eNOS等活性;术后24 h 检测血清肌酐（Cr）、尿素氮（BUN）浓度;光镜下观察肾组织病理学改变。结果：PS 组MDA显著高于S 组及ED组（P〈0.05）,PS组MPO 含量亦低于S 组及ED组（P〈0.05）。PS组SOD、eNOS 含量显著低于于S组及ED组（P〈0.05）,PS 组iNOS含量高于S 组及ED 组（P〈0.05）,ED组的肾损伤明显减轻。结论：依达拉奉能减轻肾移植缺血再灌注损伤,其机制可能与减轻肾脂质过氧化反应有关。     

重组腺病毒介导HGF修饰ADSCs对大鼠肝损伤模型的治疗作用

目的：建立重组腺病毒介导肝细胞生长因子HGF促ADSCs 定向分化肝细胞的方法,并对其参与肝损伤修复能力进行验证,为作为治疗肝损伤细胞来源提供参考。方法：采用消化培养的方法,分离SD 大鼠腹股沟脂肪组织ADSCs 细胞,连续传代3 次对其进行纯化培养,利用形态学鉴定、流式细胞术检测ADSCs 表面标志物方法对其间充质干细胞样特征进行鉴定,加入成脂肪细胞诱导液观察其分化成脂肪细胞的能力;构建腺病毒表达HGF载体Adeno-HGF-EGFP,并转染ADSCs 细胞,利用免疫细胞化学染色方法检测肝细胞标志分子表达水平;最后建立大鼠肝损伤动物模型,观察Adeno-HGF-EGFP 转染的ADSCs 细胞参与肝损伤修复能力情况。结果：分离的ADSCs 细胞形态较为一致,绝大多数呈梭形,排列不规则。流式细胞术结果显示,该细胞表达CD29、CD90、CD106 等间充质干细胞细胞表面标记物,低表达造血干细胞细胞表面标记物CD34、CD45,同时,分离的ADSCs 细胞具有诱导分化成脂肪细胞能力;Adeno-HGF-EGFP 转染ADSCs后,AFP、ALB、CK18 等肝细胞特异性分子表达水平升高;经尾静脉注射ADSCs 细胞后,肝损伤大鼠的AST、ALT、TBIL 等分子表达水平恢复正常。结论：建立了重组腺病毒介导肝细胞生长因子HGF促ADSCs定向分化肝细胞的方法,并且表达HGF的ADSCs 细胞具有修复大鼠肝损伤模型能力,这为通过细胞治疗肝损伤提供了新的细胞来源。     

三维取向PLGA神经导管促进坐骨神经再生的实验研究

目的：探讨应用改进静电纺丝技术一次成型制备三维（3D）取向聚乳酸与聚羟基乙酸共聚物（PLGA）纳米神经导管的可行性,检测其对坐骨神经再生的促进作用。方法：应用改进的静电纺丝技术制备无缝取向PLGA纳米神经导管,通过扫描电镜和透射电镜检测支架的纳米结构;分别制备取向和非取向纳米纤维支架修复13mm坐骨神经缺损模型。36只成年SD大鼠随机分为3组（每组12只）,A组：非取向PLGA神经导管组（阴性对照）;B组：取向PLGA神经导管组,C组：自体神经移植组（阳性对照）,于术后3月通过大体观察、行走足印分析、腓肠肌萎缩率、电生理检测、组织形态学检测、透射电镜检测及图像分析,评价无缝取向PLGA纳米神经导管修复坐骨神经缺损的效果。结果：神经导管修复神经缺损三月后,大体观察显示神经导管结构完整,无坍塌和断裂;各组再生神经均有通过神经导管长入远端。B组与C组的腓肠肌萎缩率和神经电传导速度无统计学差异（P〈0.05）,均优于A组。B组与C组再生神经纤维数量及成熟程度均要明显优于A组。结论：无缝取向PLGA纳米神经导管能够诱导并促进神经再生,提高坐骨神经再生的质量,有望成为自体神经移植的替代物。     

熊果苷对小鼠脑缺血再灌注损伤的影响

目的：本研究旨在探讨中药熊果苷对缺血再灌注损伤后脑细胞的影响,为中药熊果苷的临床应用提供理论依据。方法：昆明种小鼠40只,随机分成4组,即空白组、模型组、药物预防组和药物治疗组。根据缺血时脑损伤原理制成脑缺血再灌注损伤模型,以TTC染色、HE染色观察细胞形态学变化,并检测脑组织中超氧化物歧化酶（SOD）活性、丙二醛（MDA）含量及谷胱甘肽过氧化物酶（GSH-Px）活性的变化。结果：与模型组相比,药物预防组和药物治疗组分别TTC染色缺血区域都不如模型组坏死明显,HE染色显示细胞损伤程度减轻,SOD、GSH—Px活性提高有显著性差异,MDA含量减少（均P〈0．05）。结论：药物熊果苷具有抗氧化作用,能有效地预防和保护脑细胞损伤。     

急性心肌梗死患者冠脉搭桥术前中性粒细胞-淋巴细胞比率与围术期心肌损伤相关分析

目的：探讨急性心肌梗死患者冠脉搭桥（CABG）术前中性粒细胞．淋巴细胞比率（NLR）与围术期心肌损伤的关系,为,临床CABG围术期心肌保护提供参考依据。方法：选取2012年1月至2012年6月于首都医科大学附属北京安贞医院因急性心肌梗死接受冠脉搭桥手术（CABG）患者210例,收集术前血常规及术后肌钙蛋白I（cTnI）？Life酸激酶同工酶（CK-MB）,计算NLR;采用四分位法根据NLR水平将患者分为四组,比较各组cTnI及CK—MB峰值,多元逐步回归分析NLR与cTnI及CK-MB峰值的相关性。结果：随着NLR水平升高,高血压病史和射血分数〈50％患者比例逐渐增多;白细胞计数、术后CK-MB及cTnI峰值、术后血肌酐值均逐渐增加;多元逐步回归分析显示,NLR、WBC分别与cTnI峰值呈正相关（r=0．526,r=0．186,P〈0．05）。结论：术前NLR、WBC与cTnI峰值呈正相关,NLR可能是反应急性心肌梗死患者冠脉搭桥围术期心肌损伤的良好标志物。     

右美托咪定预处理对小鼠肠缺血再灌注损伤的作用研究

目的:右美托咪定(Dexmedetomidine,Dex)属于α-2肾上腺素能受体激动剂具有抗焦虑、催眠、镇痛和交感神经阻滞作用。最新研究发现右美托咪定对心脏和肺的缺血再灌注损伤具有显著的保护效应,但是右美托咪定是否对肠缺血再灌注损伤具有保护作用,迄今为止还没有相关研究。因此,本研究以小鼠为模型,观察右美托咪定预处理对小鼠肠缺血再灌注损伤的影响。方法:建立肠缺血再灌注损伤小鼠模型,并分为假手术组、缺血再灌注组和右美托咪定与处理组。不同剂量(10,25,50和100μg/kg)右美托咪定预处理小鼠。提取小鼠肠组织,用不同的试剂盒分别测定超氧化物歧化酶(Superoxide Dismutase,SOD),丙二醛(Malondialdehyde,MDA),谷胱甘肽(Glutathione,GSH),一氧化氮(Nitric Oxide,NO)和髓过氧化物酶(Myeloperoxidase,MPO)的水平变化。结果:右美托咪定预处理可以显著提高肠缺血再灌注损伤小鼠的存活率并呈剂量依赖性。右美托咪定预处理(100μg/kg)抑制由肠缺血再灌注损伤引起的不良效应,包括SOD水平降低,MDA水平升高,GSH水平降低,NO水平升高和MPO水平升高。结论:我们的研究表明右美托咪定可以提高小鼠肠缺血再灌注损伤的生存率,并且抑制氧化应激反应,炎症细胞的活化和侵润以及NO的水平,对肠缺血再灌注损伤具有显著的保护效应。本研究不仅进一步证实了右美托咪定的广泛的药理活性,而且为肠缺血再灌注损伤的治疗提供了潜在的治疗药物,其进一步的药理效应和作用机制值得进一步的研究。